Literature DB >> 18004177

Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005.

Amar Safdar1, Gilhen H Rodriguez, Marcos J De Lima, Demetrios Petropoulos, Roy F Chemaly, Laura L Worth, Elizabeth J Shpall, Kenneth V I Rolston, Issam I Raad, Ka Wah Chan, Richard E Champlin.   

Abstract

Cord blood-derived stem cells are successfully used in the treatment of cancer and congenital disorders in children. This alternative source of stem cells is also explored for adult cancer patients with limited donor options. However, delayed engraftment, prolonged neutropenia, secondary graft loss, and graft-versus-host disease (GVHD) in recipients of cord blood transplantation (CBT) make opportunistic infections a serious concern. We evaluated the spectrum of infections in adults and children undergoing CBT at our National Cancer Institute-designated comprehensive cancer center. The infection incidence rate ratio (total infection episodes/days at risk [survival after CBT] x 100) was 2.4 times higher in 35 adult patients than in 62 children, especially in adults with neutropenia (3 x higher) and GVHD (1.9 x higher). Ninety-two percent of fungal infection episodes occurred within 100 days after transplantation; half of these infections occurred in the first 30 days after CBT. Most bacterial infections (80%) were also diagnosed in the first 100 days, whereas late (>100 d) post-CBT cytomegalovirus and varicella zoster virus infections occurred only in children with chronic GVHD. Multivariate analysis showed that resolution of lymphocytopenia (> or =1000 cells/microL) (hazard ratio [HR] 0.71; p < 0.0001) and successful engraftment (HR 0.20; p < 0.0001) were associated with a low risk of serious infection. Children (HR 0.36; p < 0.0002) with sustained engraftment (HR 0.39; p < 0.004) and those with cancer in remission (HR 0.47; p < 0.007) were less likely to die from infection. More effective measures for surveillance and prevention of late cytomegalovirus and varicella zoster virus infections in children with CBT and chronic GVHD are needed.

Entities:  

Mesh:

Year:  2007        PMID: 18004177     DOI: 10.1097/MD.0b013e31815c52b0

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  15 in total

1.  Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.

Authors:  Jean El Cheikh
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

2.  Late infectious complications after cord blood stem cell transplantation.

Authors:  N G Almyroudis; J Fabian; T Hahn; B H Segal; M Wetzler; P L McCarthy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-08-12       Impact factor: 3.267

3.  Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation.

Authors:  Victor E Mulanovich; Ying Jiang; Marcos de Lima; Elizabeth J Shpall; Richard E Champlin; Stefan O Ciurea
Journal:  Am J Blood Res       Date:  2011-06-07

4.  Use of healthy-donor granulocyte transfusions to treat infections in neutropenic patients with myeloid or lymphoid neoplasms: experience in 74 patients treated with 373 granulocyte transfusions.

Authors:  Amar Safdar; Gilhen Rodriguez; Jorge Zuniga; Fadi Al Akhrass; Anupam Pande
Journal:  Acta Haematol       Date:  2013-09-19       Impact factor: 2.195

5.  The impact of CD34+ cell dose on engraftment after SCTs: personalized estimates based on mathematical modeling.

Authors:  T Stiehl; A D Ho; A Marciniak-Czochra
Journal:  Bone Marrow Transplant       Date:  2013-09-23       Impact factor: 5.483

6.  Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation.

Authors:  Stefan O Ciurea; Victor Mulanovich; Ying Jiang; Roland Bassett; Gabriela Rondon; John McMannis; Marcos de Lima; Elizabeth J Shpall; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-30       Impact factor: 5.742

Review 7.  Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.

Authors:  Christopher C Dvorak; Brian T Fisher; Lillian Sung; William J Steinbach; Michael Nieder; Sarah Alexander; Theoklis E Zaoutis
Journal:  Pediatr Blood Cancer       Date:  2011-11-18       Impact factor: 3.167

8.  Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease.

Authors:  Amar Safdar; Gilhen Rodriguez; Jorge Zuniga; Fadi Al Akhrass; Georgia Georgescu; Anupam Pande
Journal:  Acta Haematol       Date:  2012-10-02       Impact factor: 2.195

9.  Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation.

Authors:  Amar Safdar
Journal:  Curr Fungal Infect Rep       Date:  2010-03

Review 10.  Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint.

Authors:  E J Bow
Journal:  Mycopathologia       Date:  2009-04-03       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.